During the corresponding time, Legend Biotech Corporation recorded a revenue increase by 451.62 % year on year, sequentially revenue grew by 277.81 %. While revenue at the Legend Biotech Corporation's corporate clients
Legend Biotech's Comment on Sales, Marketing and Customers
The company serves the U.S. and European markets with its product CARVYKTI and plans to supply additional countries upon regulatory approval. It operates manufacturing facilities in the United States, Belgium, and China, producing commercial supplies of CARVYKTI and cilta-cel for clinical trials. To meet global demand, the company is expanding its manufacturing capacity and collaborating with third-party contract manufacturing organizations. Its long-term strategy includes establishing additional manufacturing capacity in the United States and Europe and developing regional manufacturing hubs to serve major markets. Customers include Janssen.
CARVYKTI s Impact on Minimal Residual Disease and Overall Survival in Multiple Myeloma: Insights from the CARTITUDE-4 Trial : The CARTITUDE-4 clinical trial data, conducted by Legend Biotech, highlights the efficacy of CARVYKTI (ciltacabtagene autoleucel) in treating relapsed or lenalidomide-refractory multiple myeloma. The findings demonstrate significant improvements in minimal residual disease (MRD) negativity and overall survival (OS) compared to standard therapies, offering promising advancements in multiple myeloma treatments.Multiple myeloma is a challenging hematologic malignancy characterized by complex treatment needs, especially in relapsed or refractory cases. The recent findings from Legend Bi...
Multiple myeloma (MM) poses a significant clinical challenge, particularly when patients have relapsed or have become refractory to lenalidomide, a cornerstone in MM treatment. Current standard therapies include combinations such as pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd). However, their effectiveness diminishes, and the need for superior treatment strategies is imperative. Study Overview In a groundbreaking development, Legend Biotech Corporation recently announced the late-breaking results from the Phase 3 CARTITUDE-4 study, presented at the 2024 International Myeloma Society (IMS) Annual Meeting. The study focuses on assessing the efficacy of...
Automation and Innovation: Multiply Labs and Legend Biotech s New Breakthroughs in Cell Therapy ManufacturingSAN FRANCISCO and SOMERSET, N.J. In a groundbreaking collaboration set to redefine the landscape of cell therapy manufacturing, robotics firm Multiply Labs has teamed up with the global cell therapy leader, Legend Biotech Corporation (NASDAQ: LEGN). Announced today, the partnership aims to leverage Multiply Labs cutting-edge robotic systems to automate the precise and complex processes involved in producing individualized drugs, with an initial focus on cell therapy manufacturing. Automating Cell Therapy: The Future of ManufacturingMultiply Labs is no stranger to the realm of automated solutions. ...
Legend Biotech Corporation, a global leader in cell therapy, recently shared significant findings from the Phase 2 CARTITUDE-2 Cohort D study, highlighting the effectiveness of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) in treating multiple myeloma patients. The results demonstrate that CARVYKTI produces deep and long-lasting responses in patients who have not achieved a complete response after front-line autologous stem cell transplant (ASCT). This breakthrough discovery has the potential to revolutionize the standard of care for multiple myeloma.Unveiling the Study Results:Legend Biotech s CARTITUDE-2 Cohort D study sought to assess the efficacy and safety of CARVYKTI in patients who had not responded...
Legend Biotech Corporation (NASDAQ: LEGN), a leading global player in the field of cell therapy, recently made groundbreaking announcements regarding their CAR-T cell therapy, CARVYKTI (ciltacabtagene autoleucel, or cilta-cel). This therapy aims to revolutionize the treatment landscape for patients with relapsed and refractory multiple myeloma. The company revealed new and updated data from their CARTITUDE clinical development program at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2024 European Hematology Associations (EHA) Hybrid Congress. Additionally, the European Commission (EC) granted approval for CARVYKTI for second-line treatment in Europe. The revolutionary potential...
Legend Biotech, a prominent player in the field of cell therapy, recently obtained approval from the European Commission (EC) for its breakthrough treatment, CARVYKTI (ciltacabtagene autoleucel, cilta-cel), targeting adult patients suffering from relapsed and refractory multiple myeloma. This significant achievement comes as Legend Biotech witnessed a notable revenue surge, showcasing its expanding success in the biopharmaceutical sector.Facts of the EC Approval:The European Commission has granted approval to Legend Biotech s CARVYKTI for the treatment of adult patients with relapsed and refractory multiple myeloma. To be eligible, patients must have previously undergone at least one line of therapy involvin...
Legend Biotech Corporation (NASDAQ: LEGN), a renowned global leader in cell therapy, recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expanding the label for CARVYKTI (ciltacabtagene autoleucel). The new label would include adult patients diagnosed with relapsed and refractory multiple myeloma who have previously undergone at least one therapy, incorporating an immunomodulatory agent and a proteasome inhibitor.The positive CHMP opinion signifies a significant milestone for Legend Biotech and offers hope for patients suffering from relapsed and lenalidomide refractory multiple myeloma who have limited treatment options. Th...
Legend Biotech’s Comment on Sales, Marketing and Customers
The company serves the U.S. and European markets with its product CARVYKTI and plans to supply additional countries upon regulatory approval. It operates manufacturing facilities in the United States, Belgium, and China, producing commercial supplies of CARVYKTI and cilta-cel for clinical trials. To meet global demand, the company is expanding its manufacturing capacity and collaborating with third-party contract manufacturing organizations. Its long-term strategy includes establishing additional manufacturing capacity in the United States and Europe and developing regional manufacturing hubs to serve major markets. Customers include Janssen.
Sources:
Legend Biotech Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Legend Biotech Corporation’s corporate clients.
For your research, we’ve provided 9 tables on Legend Biotech Corporation corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
72.51 %